Researchers at UCD


Patrick Mallon

College Lecturer/Consultant (Infectious Diseases)

School Of Medicine
Mater Hospital
Eccles Street
Dublin 7




Associate Dean, Research,Innovation and Impact UCD School of Medicine

Dr Patrick Mallon graduated in Medicine from Queen's University Belfast, Northern Ireland and undertook subsequent clinical training in infectious disease medicine in Sydney, Australia where he completed a PhD in the clinical and molecular aspects of HIV-associated Lipodystrophy (the commonest long-term side effect of antiretroviral therapy).

Dr Mallon returned to Ireland in 2007 to take up a consultant appointment as an Infectious Diseases Specialist at the Mater Misericordiae University Hospital, a major Irish teaching hospital that cares for a large cohort of HIV-infected patients.  He has an academic appointment at the UCD School of Medicine & Medical Science where he has led the development of the School's innovative capstone Professional Completion module within our Medicine degree programmes.
Dr Mallon heads the HIV Molecular Research Group, which focuses on translational research into toxicities of antiretroviral therapy, strategies to increase population HIV testing and studies aimed at better understanding immune responses to antiretroviral treatment. 

Dr Mallon¿s research interests include translational research into toxicities of antiretroviral therapy and cardiovascular disease, and pharmacology of anti-infectives. He has published widely in these areas and also acts as a reviewer for several international peer-reviewed medical journals.

As Associate Dean for Research, Innovation and Impact, Dr Mallon is responsible for driving the School's translational research strategy, developing research capacity, and creating a world-class support infrastructure for UCD Medicine investigators.




Conference Contributions

Cotter A, Brown A, Sheehan G, Lambert JS, Mallon P.; (2008) Patients with HIV and Hepatitis C co-infection experience less Atazanavir-induced hyperbilirubinaemia. [Poster Presentation (Refereed)], 14th Annual BHIVA Conference, Belfast, Northern Ireland , 23-APR-08 - 25-APR-08.


Year 1995 Institution: Queen's University of Belfast, UK
Qualification: MB, BCh, BAO Subject:



Book Chapters

McGinty T, Mallon PWG. (2012) 'Pharmacology of Antiretroviral Drugs' In: Somesh Gupta, Bhushan Kumar (eds). Sexually Transmitted Infections. New Delhi, India: Elsevier. , pp.805-825 [Details]

Peer Reviewed Journals

Pett SL, Amin J;Horban A;Andrade-Villanueva J;Losso M;Porteiro N;Sierra Madero J;Belloso W;Tu E;Silk D;Kelleher A;Harrigan R;Clark A;Sugiura W;Wolff M;Gill J;Gatell J;Fisher M;Clarke A;Ruxrungtham K;Prazuck T;Kaiser R;Woolley I;Arnaiz JA;Cooper D;Rockstroh JK;Mallon P;Emery S; (2016) 'Maraviroc, as a Switch Option, in HIV-1-infected Individuals With Stable, Well-controlled HIV Replication and R5-tropic Virus on Their First Nucleoside/Nucleotide Reverse Transcriptase Inhibitor Plus Ritonavir-boosted Protease Inhibitor Regimen: Week 48 Results of the Randomized, Multicenter MARCH Study'. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, . [DOI] [Details]
Tuite H, Horgan M;Mallon PW;McConkey SJ;Mooka B;Mulcahy F;Walsh C;O'Hora A;O'Flanagan D;Bergin C;Fleming C (2015) 'Patients Accessing Ambulatory Care for HIV-infection: Epidemiology and Prevalence Assessment'. Irish Medical Journal, 108 (7):199-202. [Details]
Bernardino JI, Mocroft A;Mallon PW;Wallet C;Gerstoft J;Russell C;Reiss P;Katlama C;De Wit S;Richert L;Babiker A;Bu¿¿o A;Castagna A;Girard PM;Chene G;Raffi F;Arribas JR; (2015) 'Bone mineral density and inflammatory and bone biomarkers after darunavir-ritonavir combined with either raltegravir or tenofovir-emtricitabine in antiretroviral-naive adults with HIV-1: a substudy of the NEAT001/ANRS143 randomised trial'. The lancet. HIV, 2 (11):1-73. [DOI] [Details]
O'Halloran JA, Dunne E;Gurwith M;Lambert JS;Sheehan GJ;Feeney ER;Pozniak A;Reiss P;Kenny D;Mallon P (2015) 'The effect of initiation of antiretroviral therapy on monocyte, endothelial and platelet function in HIV-1 infection'. HIV Medicine, 16 (10):608-619. [DOI] [Details]
Haskelberg H, Mallon PW;Hoy J;Amin J;Moore C;Phanuphak P;Ferret S;Belloso WH;Boyd MA;Cooper DA;Emery S (2014) 'Bone mineral density over 96 weeks in adults failing first-line therapy randomized to raltegravir/lopinavir/ritonavir compared with standard second-line therapy'. Journal of Acquired Immune Deficiency Syndromes, 67 (2):161-168. [DOI] [Details]
O'Connor G, McGinty T;Yeung SJ;O'Shea D;Macken A;Brazil E;Mallon P (2014) 'Cross-sectional study of the characteristics, healthcare usage, morbidity and mortality of injecting drug users attending an inner city emergency department'. Emergency Medicine Journal, 31 (8):625-629. [DOI] [Details]
Mallon PW (2014) 'Impact of nucleoside reverse transcriptase inhibitors on coronary heart disease'. Reviews in Cardiovascular Medicine, 15 Suppl 1 :1-9. [Details]
Tinago W, Coghlan E;Macken A;McAndrews J;Doak B;Prior-Fuller C;Lambert JS;Sheehan GJ;Mallon PW; (2014) 'Clinical, immunological and treatment-related factors associated with normalised CD4+/CD8+ T-cell ratio: effect of na¿¿ve and memory T-cell subsets'. PLoS ONE, 9 (5). [DOI] [Details]
Mallon PW (2014) 'Aging with HIV: osteoporosis and fractures'. Current Opinion in HIV and AIDS, 9 (4):428-435. [DOI] [Details]
Cotter AG, Sabin CA;Simelane S;Macken A;Kavanagh E;Brady JJ;McCarthy G;Compston J;Mallon PW; (2014) 'Relative contribution of HIV infection, demographics and body mass index to bone mineral density'. AIDS, 28 (14):2051-2060. [DOI] [Details]
Tinago, W; O'Halloran, J; O'Halloran, R; Macken, A; Lambert, J; Sheehan, G; Mallon, P; (2013) 'Characterization of associations and development of atazanavir resistance after unplanned treatment interruptions'. HIV Medicine, . [DOI] [Details]
Feeney ER, McAuley N;O'Halloran JA;Rock C;Low J;Satchell CS;Lambert JS;Sheehan GJ;Mallon PW (2013) 'The expression of cholesterol metabolism genes in monocytes from HIV-infected subjects suggests intracellular cholesterol accumulation'. Journal of Infectious Diseases, 207 (4):628-637. [DOI] [Details]
Sadlier CM, Brown A, Lambert J, Sheehan G, Mallon PW (2013) 'Seroprevalence of Schistosomiasis and Strongyloides infection in HIV-infected patients from endemic areas attending a European infectious diseases clinic'. AIDS, 10 (1). [DOI] [Details]
Cotter AG, Brown A;Sheehan G;Lambert J;Sabin CA;Mallon PW (2013) 'Predictors of the change in bilirubin levels over twelve weeks of treatment with atazanavir'. AIDS Research and Therapy, 10 (1). [DOI] [Details]
Moore R, O'Shea D;Geoghegan T;Mallon PW;Sheehan G (2013) 'Community-acquired Klebsiella pneumoniae liver abscess: an emerging infection in Ireland and Europe'. Journal of Infection, 41 (3):681-686. [DOI] [Details]
Mallon PW (2013) 'Getting to the heart of HIV and myocardial infarction'. JAMA Internal Medicine, 173 (8):622-623. [DOI] [Details]
Cotter AG, Mallon PW (2013) 'The effects of untreated and treated HIV infection on bone disease'. Current Opinion in HIV and AIDS, 9 (1):17-26. [DOI] [Details]
Sadlier, CM; Brown, A; Lambert, J; Sheehan, G; Mallon, PW (2013) 'Seroprevalence of Schistosomiasis and Strongyloides infection in HIV-infected patients from endemic areas attending a European infectious diseases clinic'. Seroprevalence of Schistosomiasis and Strongyloides infection in HIV-infected patients from endemic areas attending a European infectious diseases clinic, 10 (1). Available Online [Details]
Martin A, Moore C, Mallon PW, Hoy J, Emery S, Belloso W, Phanuphak P, Ferret S, Cooper DA, Boyd MA; Second Line study team. (2013) 'Bone mineral density in HIV participants randomized to raltegravir and lopinavir/ritonavir compared with standard second line therapy'. AIDS, 27 (18):2403-2411. [DOI] [Details]
Cotter, AG,Vrouenraets, SME,Brady, JJ,Wit, FW,Fux, CA,Furrer, H,Brinkman, K,Sabin, CA,Reiss, P,Mallon, PWG (2013) 'Impact of Switching From Zidovudine to Tenofovir Disoproxil Fumarate on Bone Mineral Density and Markers of Bone Metabolism in Virologically Suppressed HIV-1 Infected Patients; A Substudy of the PREPARE Study'. Journal of Clinical Endocrinology and Metabolism, 98 :1659-1666. [DOI] [Details]
Feeney, ER,van Vonderen, MGA,Wit, F,Danner, SA,van Agtmael, MA,Villarroya, F,Domingo, P,Capeau, J,Reiss, P,Mallon, PWG (2012) 'Zidovudine/lamivudine but not nevirapine in combination with lopinavir/ritonavir decreases subcutaneous adipose tissue mitochondrial DNA'. AIDS, 26 :2165-2174. [DOI] [Details]
Fox D, O'Connor R, Mallon P, McMahon G. (2011) 'Simultaneous determination of efavirenz, rifampicin and its metabolite desacetyl rifampicin levels in human plasma'. Journal of Pharmaceutical and Biomedical Analysis, 56 (4):785-791. [Details]
Satchell CS, O'Halloran JA;Cotter AG;Peace AJ;O'Connor EF;Tedesco AF;Feeney ER;Lambert JS;Sheehan GJ;Kenny D;Mallon PW (2011) 'Increased platelet reactivity in HIV-1-infected patients receiving abacavir-containing antiretroviral therapy'. Journal of Infectious Diseases, 204 (8):1202-1210. [DOI] [Details]
Feeney ER, Mallon PW (2011) 'Insulin resistance in treated HIV infection'. Best Practice and Research in Clinical Endocrinology and Metabolism, 25 (3):443-458. [DOI] [Details]
Cotter AG, Satchell CS;O'halloran JA;Feeney ER;Sabin CA;Mallon PW (2011) 'High-density lipoprotein levels and 10-year cardiovascular risk in HIV-1-infected patients'. AIDS, 25 (6):867-869. [DOI] [Details]
Feeney ER, Mallon PW (2011) 'HIV and HAART-Associated Dyslipidemia'. Open Cardiovascular Medicine Journal, 5 :49-63. [DOI] [Details]
Cotter AG, Mallon PW (2011) 'HIV infection and bone disease: implications for an aging population'. Sexual Health, 8 (4):493-501. [DOI] [Details]
Feeney, ER,Chazallon, C,O'Brien, N,Meiffredy, V,Goodall, RL,Aboulker, JP,Cooper, DA,Yeni, P,Mallon, PWG (2011) 'Hyperlactataemia in HIV-infected subjects initiating antiretroviral therapy in a large randomized study (a substudy of the INITIO trial)'. HIV Medicine, 12 :602-609. [DOI] [Details]
Feeney ER, Chazallon C, O¿Brien N, Meiffredy V, Goodall RL, Aboulker JP, Cooper DA, Yeni P, Mallon PWG on behalf of the INITIO Trial International Co-ordinating Committee. (2011) 'Risk factors associated with lactic acidosis / symptomatic hyperlactatemia for HIV-infected patients on antiretroviral therapy enrolled in a randomised clinical trial: a sub-study of the INITIO trial'. HIV Medicine, 12 (10):602-609. [DOI] [Details]
Kearney H, Mallon P, Kavanagh E, Lawler L, Kelly P, O¿Rourke K. (2010) 'Amnestic syndrome due to meningovascular neurosyphilis'. Neurology, 257 (4):669-671. [Details]
Feeney ER, Mallon PW (2010) 'Impact of mitochondrial toxicity of HIV-1 antiretroviral drugs on lipodystrophy and metabolic dysregulation'. Current Pharmaceutical Design, 16 (30):3339-3351. [Details]
Satchell, CS,Cotter, AG,O'Connor, EF,Peace, AJ,Tedesco, AF,Clare, A,Lambert, JS,Sheehan, GJ,Kenny, D,Mallon, PWG; (2010) 'Platelet function and HIV: a case-control study'. AIDS, 24 :649-657. [DOI] [Details]
Mallon PW; (2010) 'HIV and bone mineral density'. Current Opinion in Infectious Diseases, 23 (1):1-8. [DOI] [Details]
Read TR, Carey D, Mallon P, Mijch A, Goodall R, Hudson F, Wand H, Emery S. (2009) 'Efavirenz plasma concentrations did not predict cessation of therapy due to neuropsychiatric symptoms in a large randomized trial'. AIDS, 23 (16):2222-2223. [Details]
Yilmaz, A,Izadkhashti, A,Price, RW,Mallon, PW,De Meulder, M,Timmerman, P,Gisslen, M; (2009) 'Darunavir Concentrations in Cerebrospinal Fluid and Blood in HIV-1-Infected Individuals'. AIDS, 25 :457-461. [DOI] [Details]
Doran PP, Cotter EJ, Mallon PW, ; (2009) 'Is PPARgamma a Prospective Player in HIV-1-Associated Bone Disease?'. PPAR Research, 2009 (NA). [DOI] [Details]
Gallagher, D. P., Kieran, J., Sheehan, G., Lambert, J., Mahon, N., Mallon, P. W. G. (2008) 'Ritonavir-boosted atazanavir, methadone, and ventricular tachycardia: 2 case reports'. Clinical Infectious Diseases, 47 (3):36-38. [Details]
Carr A, Mallon PW, Sedwell R, Rogers G, Nolan D, Unemori P, Hoy J, Samaras K, Kelleher A, Emery S, Cooper DA, ; (2008) 'Effect of rosiglitazone on peroxisome proliferator-activated receptor gamma gene expression in human adipose tissue is limited by antiretroviral drug-induced mitochondrial dysfunction'. Journal of Infectious Diseases, 12 (NA):1794-1803. [DOI] [Details]
Mallon, PWG (2007) 'Antiretroviral therapy-induced lipid alterations: in-vitro, animal and human studies'. Current Opinion in HIV and AIDS, 2 :282-292. [DOI] [Details]

Other Journals

Mallon PW, Powderly WG; (2009) 'Management of late presentation of HIV: what the data tell us' HIV Therapy 3 :423-426. [Details]

Conference Publications

Mallon, PWG,Sedwell, R,Rogers, G,Nolan, D,Unemori, P,Hoy, J,Samaras, K,Kelleher, A,Emery, S,Cooper, DA,Carr, A (2008) JOURNAL OF INFECTIOUS DISEASES Effect of Rosiglitazone on Peroxisome Proliferator-Activated Receptor gamma Gene Expression in Human Adipose Tissue Is Limited by Antiretroviral Drug-Induced Mitochondrial Dysfunction , pp.1794-1803 [DOI] [Details]


Murray, BF,van Vonderen, MG,Mallon, PW,Doran, P,van Agtmael, MA,Danner, SA,Lips, P,Reiss, P (2012) Changes in bone biomarkers in antiretroviral naive HIV-infected men randomised to nevirapine/lopinavir/ritonavir (NVP/LPV/R) or zidovudine/lamivudine/lopinavir/ritonavir (AZT/3TC/LPV/R) help explain limited loss of bone mineral density over first 12 months. Abstract [DOI] [Details]
Cotter, AG,Satchell, CS,O'Halloran, J,Feeney, ER,Sabin, CA,Mallon, PWG (2010) High-density lipoprotein levels and 10-year cardiovascular risk in HIV-1 infected patients. Abstract [Details]
Satchell, CS,O'Halloran, JA,Peace, AJ,O'Connor, EF,Cotter, AG,Feeney, ER,Sheehan, GJ,Lambert, JS,Kenny, D,Mallon, PWG (2010) Inflammation and impaired renal function do not explain increased platelet reactivity in patients on abacavir-containing antiretroviral therapy. Abstract [Details]
Cotter, EJ,Feeney, ER,Mallon, PW,Murray, PT,Powderly, WG,Doran, PP (2010) Role of reactive oxygen species (ROS) and TGF-beta in tenofovir-induced renal tubular toxicity. Abstract [Details]
Cotter, AG,Satchell, CS,O'Halloran, J,Feeney, ER,Sabin, CA,Mallon, PWG (2010) High-density lipoprotein levels and 10-year cardiovascular risk in HIV-1 infected patients. Abstract [Details]
Cotter, AG,Satchell, CS,O'Halloran, J,Feeney, ER,O'Connor, E,Sheehan, G,Lambert, J,Sabin, CA,Mallon, PWG (2010) The protease inhibitor atazanavir and predictors of prolonged QT interval in HIV-1 infected patients. Abstract [Details]
Satchell, CS,O'Halloran, JA,Peace, AJ,O'Connor, EF,Cotter, AG,Feeney, ER,Sheehan, GJ,Lambert, JS,Kenny, D,Mallon, PWG (2010) Inflammation and impaired renal function do not explain increased platelet reactivity in patients on abacavir-containing antiretroviral therapy. Abstract [Details]
Cotter, AG,Satchell, CS,O'Halloran, J,Feeney, ER,O'Connor, E,Sheehan, G,Lambert, J,Sabin, CA,Mallon, PWG (2010) The protease inhibitor atazanavir and predictors of prolonged QT interval in HIV-1 infected patients. Abstract [Details]
Mallon, PW (2010) Bone ageing and HIV. Abstract [DOI] [Details]
Cotter, EJ,Feeney, ER,Mallon, PW,Murray, PT,Powderly, WG,Doran, PP (2010) Role of reactive oxygen species (ROS) and TGF-beta in tenofovir-induced renal tubular toxicity. Abstract [Details]
Distler, O,Mallon, PW,Kelleher, AD,Carr, A,Calmy, A,Cooper, DA (2009) Evaluation of adipose gene expression and mitochondrial DNA in healthy adults over a 6 week course of NRTI and/or PI treatment. Indications of divergent effects. Abstract [Details]
Barnes, TE,Mallon, PWG (2008) In vitro alterations in hepatocyte mitochondrial RNA expression and DNA content following long-term exposure to reverse transcriptase inhibitor combinations. Abstract [Details]


Post, FA,McCloskey, EV,Compston, JE,Bowman, CA,Hay, PE,Johnson, MA,Mallon, PWG,Peters, BS,Samarawickrama, A,Tudor-Williams, G (2011) Prevention of bone loss and management of fracture risk in HIV-infected individuals: case studies and recommendations for different patient subgroups. Reviews [DOI] [Details]
Mallon, PWG (2010) HIV and bone mineral density. Reviews [DOI] [Details]
Feeney, ER,Mallon, PWG (2010) Impact of Mitochondrial Toxicity of HIV-1 Antiretroviral Drugs on Lipodystrophy and Metabolic Dysregulation. Reviews [Details]
Cotter, EJ,Mallon, PW,Doran, PP (2009) Is PPAR gamma a Prospective Player in HIV-1-Associated Bone Disease?. Reviews [DOI] [Details]


Kearney, H,Mallon, P,Kavanagh, E,Lawler, L,Kelly, P,O'Rourke, K (2010) Amnestic syndrome due to meningovascular neurosyphilis. Letters [DOI] [Details]


Research Interests


HIV Molecular Research Group Overview

Established in 2008, the HIV Molecular Research Group (HMRG) is internationally recognized for its translational research into long-term co-morbidities associated with HIV infection and its treatment with antiretrovirals and re- search into models of testing to increase early diagnosis of HIV.

The HMRG, based on the Mater Misericordiae University Hospital (MMUH) campus, coordinates international, collaborative, translational research in HIV. The group comprises researchers with laboratory, statistical and clinical re- search expertise and is funded through a number of streams including Science Foundation Ireland, the Health Research Board and several industry supporters.The groups research focuses around four principal themes (described below).

The groups research focuses around four principal themes:

  1. Models of HIV detection.The Mater-Bronx Rapid HIV Testing Project M-BRiHT, involves collaborations between UCD, MMUH and the Jacobi Medical Centre in the Bronx, New York, and aims to increase early detection of HIV, a core strategy to reduce onward HIV transmission. M-BRiHT combines rapid HIV testing with novel, computer-based video counseling and offers unselected HIV screening to attendees to the MMUH Emergency Department. Sponsored by UCD and funded by Gilead Sciences, M-BRiHT launched in September 2012 and has already recruited over 4,000 subjects, with plans for international expansion to sites in the UK and Italy in 2013.
  2. Bone disease in HIV. Low bone mineral density and osteoporosis is com- mon in those with HIV.The HMRG coordinates a number of international projects to define the natural history and pathogenesis of bone disease in HIV, including the establishment of the HIV UPBEAT cohort, the largest international prospective cohort of HIV positive and negative subjects (N=484). With funding from the Health Research Board and GlaxoSmithKline, HIV UPBEAT has started to yield very exciting results that will be published in 2013.
  3. Cardiovascular disease (CVD) is also increased in HIV. The Reverse Cholesterol Transport Study (RCTS), co-funded by the EU through the European AIDS Treatment Network (NEAT) and Science Foundation Ireland is exploring mechanisms of dyslipidaemia in HIV. RCTS expands on early work by HMRG published in the Journal of Infectious Diseases in 2012 on mechanisms of increased CVD in HIV, and is recruiting 100 subjects with HIV at MMUH and the Chelsea and Westminster Hospital in London.
  4. HIV Immunology. Through the MMUH ID Cohort Project, the HIV Immunology Study, supported by a number of industry partners aims to explore additional therapy. This study, in collaboration with Rush University Medical Centre in Chicago, has recruited over 200 subjects.

In addition to a number of publications and conference presentations, HMRG¿s achievements were recognized in 2012 with the award, by the British HIV Association, of the ¿Brian Gazzard Lectureship in HIV Medicine¿ to Dr Mallon. 
Major ongoing studies include the HIV UPBEAT Study, the largest, prospective controlled study into bone disease in HIV internationally, the M-BRiHT Study ¿ one of the largest European Emergency Department-based HIV screening research programmes, with over 7,000 subjects recruited in just over 16 months, and the Mater Immunology Study, part of the Mater ID Cohort Project. The HMRG also participates in numerous international collaborative trials, such as the START Study and the NEAT001 study. The HMRG has attracted significant funding from both Science Foundation Ireland and the Health Research Board together with funding from pharmaceutical companies including Merck Sharp and Dohme, GlaxoSmithKline, Gilead and Pfizer.


Research Projects

Sponsor : European Commission FP6
Title : European Collaboration on Aids Trials
Start Date / End Date : 01-FEB-07 / 31-JUL-13
Sponsor : Irish Lung Foundation
Title : Study of pharmacokinetics of efavirenz and rifampicin (SPhEAR study)
Start Date / End Date : 01-AUG-07 / 30-JUL-08
Sponsor : HEA/PRTLI Cycle 4 Grant
Title : Biomedical Sciences Network
Start Date / End Date : 01-JUL-08 / 30-JUN-11
Sponsor : University College Dublin (UCD)
Title : HIV Molecular Group Research Project.
Start Date / End Date : 01-JUL-08 / 30-JUN-09
Sponsor : Science Foundation Ireland (SFI)
Title : Exploring antiretroviral-induced adipose tissue toxicity through translational research
Start Date / End Date : 01-AUG-09 / 31-JUL-13
Sponsor : Health Research Board (HRB)
Title : The effect of HIV and HAART on genes involved in reverse cholesterol transport in monocytes
Start Date / End Date : 21-JUN-10 / 13-AUG-10
Sponsor : Health Research Board (HRB)
Title : Examining markers of adipocyte differentiation and mitochondrial mass in primary cultures of human adipocytes exposed to antitretroviral drugs
Start Date / End Date : 01-JUL-10 / 31-AUG-10
Sponsor : Health Research Board (HRB)
Title : Exploring Low Bone Mineral Density in HIV
Start Date / End Date : 01-OCT-10 / 01-OCT-13
Sponsor : GlaxoSmithKline (Ireland) Ltd.
Title : Understanding the pathology of bone disease in HIV-infected patients
Start Date / End Date : 01-DEC-10 / 01-MAY-14
Sponsor : Imperial College of Science Technology and Medicine
Title : SMASH study
Start Date / End Date : 01-DEC-10 / 01-MAR-12
Sponsor : Merck Sharp & Dohme (Ireland)
Title : Mater HIV-ID Cohort Project - MSD
Start Date / End Date : 19-SEP-11 / 18-SEP-14
Sponsor : Janssen-Cilag Ltd.
Title : Mater HIV-ID Cohort Project - Janssen
Start Date / End Date : 01-NOV-11 / 31-DEC-13
Sponsor : Gilead Sciences
Title : The Mater Bronx Rapid HIV Testing Project (M-BRiHT Project)
Start Date / End Date : 02-JAN-12 / 31-DEC-14
Sponsor : AiCuris GmbH & Co. KG
Title : In vitro examination of toxocity of investigational agents - Aicuris.
Start Date / End Date : 06-FEB-12 / 31-DEC-12
Sponsor : Health Research Board (HRB)
Title : HRB Bone KEDS
Start Date / End Date : 23-NOV-12 / 01-OCT-13
Sponsor : Gilead Sciences
Title : SWIFT Study: Switching from Lamivudine/Abacavir (3TC/ABC) to Emtricitabine/Tenofovir DF (FTC/TDF) Based Regimen ¿ Platelet and Inflammation Sub-study
Start Date / End Date : 28-JAN-13 / 31-JUL-14
Sponsor : Gilead Sciences
Title : 3M-BRiHT Project - Mater-Manchester-Modena-Bronx Rapid HIV Testing Project
Start Date / End Date : 01-FEB-13 / 30-APR-14
Sponsor : Gilead Sciences
Title : GS-US-311-1717 Platelet sub-study
Start Date / End Date : 15-OCT-15 / 15-OCT-20
Sponsor : Imperial College London (ICL)
Title : Pharmacokinetic and Clinical Observations in People over Fifty - POPPY
Start Date / End Date : 19-SEP-14 / 18-SEP-16
Sponsor : Health Research Board (HRB)
Title : Alendronate for Prevention of Antiretroviral Therapy-associated bone loss (APART) Study.
Start Date / End Date : 01-SEP-14 / 31-AUG-18
Sponsor : Bristol Myers Squibb Pharmaceuticals
Title : Mater HIV/ID Cohort Project - BMS
Start Date / End Date : 21-DEC-12 / 31-DEC-15

Current Postgraduate Students

Tara Mc Ginty, Doctor of Philosophy (PhD)   -   Thesis Supervisor
Jillian Musarra, Social Science (MSocSc)   -   Secondary Supervisor
Jane O'Halloran, Doctor of Philosophy (PhD)   -   Thesis Supervisor



External Collaborators

  • Prof Caroline Sabin, University College London, HIV UPBEAT and HRB Bone 
  • Prof Juliet Compston, University of Cambridge, HIV UPBEAT
  • Prof Yvette Calderon, Jacobi medical Centre, Albert Einstein College of Medicine, the Bronx, New York, M-BRiHT 
  • Prof Peter Reiss, University of Amsterdam, RCTS Study
  • Prof Alan Landay, Rush University Medical Centre, Chicago HIV Immunology Study 
  • Prof Dermot Kenny, Royal College of Surgeons in Ireland, Platelet Dysfunction in HIV
  • Dr Anton Pozniak, St Stephens AIDS Trust the Chelsea and Westminster Hospital, London RCTS Study